OKI-179 + binimetinib
OKI-179-230
Phase 2 small_molecule completed
Quick answer
OKI-179 + binimetinib for RAS Mutation is a Phase 2 program (small_molecule) at OnKure Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- OnKure Therapeutics
- Indication
- RAS Mutation
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed